본 보고서는 폐 전이를 동반한 연부육종의 역학, 시장, 임상개발에 대한 상세한 분석을 제공하고 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본에서의 폐 전이를 동반한 연부육종의 역학 및 시장 규모 추이와 예측 데이터 및 시장 동향의 상세한 분석을 제공합니다.
또한 실제 처방 패턴 분석, 신규약제 평가, 시장 점유율, 치료제별 채택·보급 패턴, 현재의 폐 전이를 수반하는 연부육종 치료의 실천/알고리즘과 암메트니즈도 망라하여 최적 시장 기회를 파악하고 폐 전이를 수반하는 연부육종 시장이 가지는 잠재가치를 평가했습니다.
DelveInsight's "Soft tissue sarcoma (STS) with Lung Metastasis Market- Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of STS with lung metastasis epidemiology, market, and clinical development in STS with lung metastasis with lung metastasis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the STS with lung metastasis with lung metastasis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
The STS with lung metastasis with lung metastasis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted STS with lung metastasis with lung metastasis market size from 2020 to 2034 in 7MM. The report also covers current STS with lung metastasis with lung metastasis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Soft Tissue Sarcoma with Lung Metastasis Overview and Diagnosis
Soft tissue sarcoma (STS) is a diverse group of rare malignant tumors that originate in the mesodermal tissues-such as fat, muscle, blood vessels, deep skin layers, tendons, and ligaments-that support and connect various parts of the body. While these tumors can occur anywhere, they most often begin in the arms or legs, but can also develop in the trunk, head and neck, internal organs, or the retroperitoneal space (the area behind the abdominal cavity). One of the major challenges in STS is its potential to spread beyond the original tumor site. Metastasis is not uncommon; in fact, approximately 40% to 50% of individuals with STS will eventually develop metastatic disease. Among all possible sites, the lungs are by far the most common destination for metastases, accounting for nearly 80% of first metastatic occurrences. When STS spreads to the lungs, it typically signals a more advanced stage of the disease, requiring a shift in treatment goals-from curative intent to controlling disease progression, alleviating symptoms, and extending survival. STS with lung metastasis is diagnosed through a combination of imaging scans, biopsies, and sometimes blood tests. Imaging, like chest X-rays, CT scans, or MRIs, can reveal the presence of tumors in the lungs. Biopsies, where tissue samples are examined under a microscope, confirm the diagnosis and determine the specific type of sarcoma.
The STS with lung metastasis report provides an overview of STS with lung metastasis pathophysiology, and diagnostic approaches, along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.
Soft tissue sarcoma with lung metastasis Treatment
Pulmonary metastases are a sign of advanced disease and are always a challenge in the management of oncologic patients. The mainstay of treatment is the surgical resection of all metastatic nodules which offers a potentially curative option and a significant survival advantage. In the setting of metastatic sarcoma, lung involvement is frequent, and the disease tends to recur with a significantly higher pattern than in any other tumor type. Multiple or even extended operations are often necessary. Alongside the operative approach, medical therapy has been reported with variable results. Currently, single-agent chemotherapy or combinations are reserved for patients with chemosensitive histology or patients considered for multimodality therapy. The role of immunotherapy, instead, despite promising results, is still under investigation. Radiotherapy has been boosted in recent years, with the spread of stereotactic body radiation therapy which overwhelmed the traditional sarcomas' radioresistance.
As the market is derived using a patient-based model, the STS with lung metastasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of STS, total incident cases of STS with lung metastasis, gender-specific cases of STS with lung metastasis, age-specific cases of STS with lung metastasis, and total treated cases of STS with lung metastasis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the STS with lung metastasis report encloses a detailed analysis of STS with lung metastasis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the STS with lung metastasis's pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Emerging Drugs
Annamycin: Moleculin Biotech
Annamycin is a next-generation anthracycline being developed by Moleculin Biotech for hard-to-treat cancers, including STS with lung metastases. Unlike traditional anthracyclines, Annamycin has shown no evidence of cardiotoxicity in clinical trials, allowing for potentially higher cumulative dosing beyond FDA-set lifetime limits. This could make it a safer and more potent option in advanced STS, where standard anthracycline use is often restricted due to cardiac risks. The drug has received US FDA Orphan Drug and Fast Track Designations specifically for STS with lung metastases and is currently being evaluated in a Phase Ib/II clinical trial.
Volrustomig (MEDI5752): Institut Claudius Regaud/AstraZeneca
MEDI5752 is an anti PD-1/CTLA-4 bispecific antibody developed by AstraZeneca. The company is conducting Phase I trial of MEDI5752 in combination with SBRT delivered on one lung metastatic lesion, in patients with metastatic soft tissue sarcoma.
The gold standard for patients with localized STSs is surgical-wide resection with oncologic margins. In contrast, STS patients with metastatic lesions are treated by systemic chemotherapy, radiation, and possibly with resection of the primary tumor or metastatic lesions. Doxorubicin, the first-line palliative chemotherapy, is recommended as a therapeutic option for the majority of STS patients with Lung Metastases. Pulmonary metastasectomy is also a proven standard approach for the management of STS patients with LM, and some published studies have indicated that 5-year overall survival (OS) ranges from 43% to 50.9% in patients following this procedure. In addition, Matsuoka et al reported surgical resection of a primary tumor in the extremities could improve survival for metastatic STS patients. Despite efforts to improve the clinical outcome of these patients, the prognosis remains poor.
There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are used to manage metastatic STS, none are uniquely indicated for lung metastases. Few companies are conducting trials for this segment such as Moleculin Biotech, AstraZeneca, and others.
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Soft tissue sarcoma with lung metastasis Cancer Activities
The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for STS with lung metastasis emerging therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.
DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, University of Michigan, and Sarcoma Oncology Center etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or STS with lung metastasis market trends.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.